Library Header Image
LSE Research Online LSE Library Services

The COVID-19 innovation system

Sampat, Bhaven N. and Shadlen, Kenneth C. ORCID: 0000-0003-4010-4835 (2021) The COVID-19 innovation system. Health Affairs, 40 (3). 400 - 409. ISSN 0278-2715

Full text not available from this repository.

Identification Number: 10.1377/hlthaff.2020.02097


The coronavirus disease 2019 (COVID-19) pandemic response brought forth major changes in innovation policy. This article takes stock of the key features of the COVID-19 innovation system-the network of public and private actors influencing the development and diffusion of technologies to combat the pandemic. Before the pandemic, biomedical research and development policy consisted largely of "push" funding from the public sector in support of basic research and "pull" incentives from patents to motivate private companies to invest in clinical trials and develop drugs and vaccines. In contrast, during the pandemic, public funding shifted its focus to late-stage product development and manufacturing. Procurement agreements with governments replaced traditional pull incentives from patents for the major private companies. Nonpatent barriers to competition may also have incentivized innovation. The challenges to ensuring diffusion have gained in prominence during the pandemic, though it is unclear what role patents will play in pricing and access. Some aspects of this approach to biomedical innovation may be unique to crises, but others could provide lessons for policy beyond the pandemic.

Item Type: Article
Official URL:
Additional Information: © 2021 Project HOPE—The People-to-People Health Foundation, Inc
Divisions: International Development
Subjects: R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
H Social Sciences > HV Social pathology. Social and public welfare. Criminology
Date Deposited: 19 Jan 2021 10:39
Last Modified: 18 Feb 2024 19:15

Actions (login required)

View Item View Item